An experimental weekly injection called survodutide helped adults with obesity or overweight and type 2 diabetes lose up to 13.1% of their body weight over 76 weeks, compared with 3.1% on placebo. The phase 3 results were published Oct. 1 in The New England Journal of Medicine and presented at the European Association for the Study of Diabetes annual meeting.
The drug is not approved by the FDA, and the trial was run by its developer, Boehringer Ingelheim. It also had a notable drawback: 18% of people on survodutide stopped treatment because of stomach side effects, compared with 1.2% on placebo.
